Stock EW EDWARDS LIFESCIENCES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Edwards Lifesciences Corporation

Equities

EW

US28176E1082

Advanced Medical Equipment & Technology

Market Closed - Nyse
Other stock markets
 16:00:02 2024-04-26 EDT 		5-day change 1st Jan Change
86.43 USD -1.80% Intraday chart for Edwards Lifesciences Corporation +0.57% +13.35%
04-26 Evercore ISI Adjusts Price Target on Edwards Lifesciences to $89 From $92 MT
04-26 Stifel Adjusts Price Target on Edwards Lifesciences to $85 From $83 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 48,657 56,859 80,883 46,128 46,246 52,025 - -
Enterprise Value (EV) 1 48,073 56,271 80,616 45,956 45,198 50,327 49,134 46,952
P/E ratio 47.3 x 70.2 x 54.4 x 30.6 x 33.2 x 32.4 x 28.5 x 26 x
Yield - - - - - - - -
Capitalization / Revenue 11.2 x 13 x 15.5 x 8.57 x 7.7 x 7.93 x 7.24 x 6.61 x
EV / Revenue 11.1 x 12.8 x 15.4 x 8.54 x 7.53 x 7.67 x 6.84 x 5.97 x
EV / EBITDA 34.2 x 39.4 x 46.6 x 23.7 x 24.1 x 24.2 x 20.9 x 18.2 x
EV / FCF 52 x 86.9 x 57.3 x 47.2 x 47.9 x 39 x 29.6 x 25.6 x
FCF Yield 1.92% 1.15% 1.74% 2.12% 2.09% 2.57% 3.37% 3.9%
Price to Book 12 x 12.7 x 13.9 x 7.82 x 6.99 x 7.14 x 6.1 x 5.2 x
Nbr of stocks (in thousands) 625,710 623,248 624,334 618,260 606,500 601,927 - -
Reference price 2 77.76 91.23 129.6 74.61 76.25 86.43 86.43 86.43
Announcement Date 20-01-30 21-01-27 22-01-26 23-01-31 24-02-06 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 4,348 4,386 5,232 5,382 6,005 6,559 7,188 7,870
EBITDA 1 1,406 1,429 1,729 1,936 1,879 2,080 2,355 2,586
EBIT 1 1,316 1,322 1,594 1,796 1,734 1,902 2,159 2,417
Operating Margin 30.28% 30.14% 30.47% 33.38% 28.87% 29% 30.03% 30.71%
Earnings before Tax (EBT) 1 1,166 916.7 1,702 1,767 1,598 1,912 2,217 2,489
Net income 1 1,047 823.4 1,503 1,522 1,402 1,610 1,840 2,016
Net margin 24.08% 18.77% 28.73% 28.28% 23.35% 24.55% 25.59% 25.61%
EPS 2 1.643 1.300 2.380 2.440 2.300 2.667 3.038 3.318
Free Cash Flow 1 925 647.3 1,406 973.6 943 1,291 1,657 1,833
FCF margin 21.27% 14.76% 26.88% 18.09% 15.7% 19.68% 23.06% 23.28%
FCF Conversion (EBITDA) 65.8% 45.29% 81.32% 50.29% 50.19% 62.06% 70.39% 70.86%
FCF Conversion (Net income) 88.36% 78.61% 93.56% 63.97% 67.24% 80.17% 90.1% 90.91%
Dividend per Share 2 - - - - - - - -
Announcement Date 20-01-30 21-01-27 22-01-26 23-01-31 24-02-06 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 1,310 1,330 1,341 1,374 1,319 1,348 1,460 1,530 1,481 1,534 1,598 1,656 1,622 1,685 1,741
EBITDA 1 431.4 398 479.4 480 492.8 483.9 469.3 485.6 458.7 465.1 494.3 522.7 514.7 542.5 557.6
EBIT 1 397.8 365 444.7 445.9 457.4 448.5 434.1 449.5 421.8 428.4 439.1 479.8 475.4 501.8 513.7
Operating Margin 30.36% 27.45% 33.16% 32.46% 34.68% 33.26% 29.74% 29.38% 28.48% 27.93% 27.47% 28.98% 29.32% 29.78% 29.51%
Earnings before Tax (EBT) 1 390.9 376.3 436.1 464.7 407.3 459.3 398.6 338.5 439.3 421.7 409.4 492.4 486.7 507.6 524
Net income 1 340.1 335.3 373.6 406.4 343.5 398.4 340.5 307.1 384.9 369.9 351.9 412.6 407.4 428.5 434.5
Net margin 25.96% 25.22% 27.86% 29.58% 26.04% 29.55% 23.33% 20.07% 25.99% 24.11% 22.02% 24.92% 25.12% 25.43% 24.96%
EPS 2 0.5400 0.5300 0.5900 0.6500 0.5500 0.6500 0.5600 0.5000 0.6300 0.6100 0.5800 0.6816 0.6722 0.7120 0.7222
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 21-10-27 22-01-26 22-04-26 22-07-28 22-10-27 23-01-31 23-04-26 23-07-26 23-10-25 24-02-06 24-04-25 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 585 588 267 173 1,048 1,697 2,890 5,073
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 925 647 1,406 974 943 1,291 1,657 1,833
ROE (net income / shareholders' equity) 32.5% 26.9% 27% 26.6% 22.5% 22.6% 23.3% 22.3%
ROA (Net income/ Total Assets) 20% 17.1% 17.8% 18.5% 15.9% 17.2% 16.6% 15.5%
Assets 1 5,227 4,814 8,426 8,242 8,828 9,359 11,107 12,979
Book Value Per Share 2 6.500 7.190 9.350 9.550 10.90 12.10 14.20 16.60
Cash Flow per Share 2 1.850 1.670 2.740 1.950 1.470 2.910 3.250 3.470
Capex 1 254 407 326 245 253 305 314 331
Capex / Sales 5.85% 9.28% 6.23% 4.54% 4.21% 4.64% 4.37% 4.21%
Announcement Date 20-01-30 21-01-27 22-01-26 23-01-31 24-02-06 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Edwards Lifesciences Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
86.43 USD
Average target price
94.63 USD
Spread / Average Target
+9.48%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.35% 52.02B
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.07% 219B
DANAHER CORPORATION Stock Danaher Corporation
+6.59% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.26% 133B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.57% 108B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+0.65% 63.06B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.62% 48.2B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.93% 40.37B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.54% 39.35B
RESMED, INC. Stock ResMed, Inc.
+26.76% 32.03B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. EW Stock
  4. Financials Edwards Lifesciences Corporation